The benefit of primary percutaneous coronary intervention is limited by a 5% to 20% incidence of suboptimal epicardial coronary blood (≤ TIMI-2 flow). Recently, data has demonstrated that when administered in conjunction with primary stenting for the treatment of acute myocardial infarction (AMI), abciximab improves the success rate of the stenting procedure and provides additional clinical benefits. But data on a combination of tirofiban and primary stenting for treatment of ST-segment elevated (ST-se) AMI is unknown.
THE benefit of reperfusion therapy for acute myocardial infarction (AMI) has been attributed to brisk reestablishment of normal flow [Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow: TIMI grade 3 flow] in the infarct-related artery (IRA). [1] [2] [3] Primary percutaneous coronary intervention (primary PCI), which is one of the standard treatments for AMI, significantly improves patient survival in this clinical setting and is superior to thrombolytic therapy in terms of immediate restoration of normal coronary flow in the IRA and reduction of recurrent ischemia or reinfarction. 4, 5) However, the benefits of primary PCI are limited by a 5% to 20% incidence of suboptimal epicardial coronary blood (≤ TIMI-2 flow). [4] [5] [6] [7] [8] This unsuccessful reperfusion is associated with relatively more extensive myocardial necrosis, 9) and consequently left ventricular dilatation with poor regional and global contractile function and a poor prognosis. 4, 10, 11) The putative mechanisms of slow flow or no reflow phenomenon after PCI have been discussed extensively. [12] [13] [14] However, the treatment of suboptimal epicardial coronary flows during primary PCI remains problematic.
Recently, some clinical trials have demonstrated that when administered in conjunction with primary PCI for the treatment of AMI, abciximab improves the success rate of the stenting procedure and provides additional clinical benefits. 15, 16) Another recent randomized clinical trial, the PRISM-PLUS trial 17) demonstrated that the addition of tirofiban to heparin reduced the thrombus burden in the culprit lesion and improved distal perfusion in patients with unstable angina or non-Q-wave myocardial infarction. However, we could find no data on a combination of tirofiban and primary stenting for treatment of ST-segment elevated (ST-se) AMI. We hypothesized that preinterventional administration of tirofiban followed by stenting would be superior to stenting alone in terms of immediate restoration of normal coronary blood flow and 30-day clinical outcomes.
METHODS

Study patients:
Between January 2001 and April 2002, tirofiban was administered before primary stenting to 133 consecutive patients (study group) who presented with an ST-se AMI of < 12 hours duration in our hospital (patients with cardiogenic shock within 18 hours were also enrolled in the study) and had no Vol 45 No 1 contraindications for tirofiban. All of these patients were prospectively identified and entered into a computerized database. Previous studies 7, 15, 16) have demonstrated the clinical benefits of platelet glycoprotein (PG) IIb/IIIa inhibitor therapy when administered in conjunction with primary PCI for AMI. Therefore, it would have been unethical to perform a randomized study to determine whether primary stenting with adjunctive tirofiban therapy is superior to primary stenting alone in terms of angiographic and clinical outcomes in patients with AMI. Thus, between May 1999 and September 2000, 136 consecutive and unselected patients who had AMI and received primary stenting without adjunctive PG IIb/IIIa inhibitor therapy served as controls (control group). Procedure and protocol: PG IIb/IIIa receptor antagonists have been available in our country since August 2001. At the time of our study, our government medical insurance only paid for tirofiban for patients with AMI. In our hospital, all patients with AMI are considered eligible for primary PCI and tirofiban is given after informed consent is obtained unless there are contraindications. The protocol-designated dosage was a bolus dose of 10 micrograms per kilogram of body weight given to patients upon presentation in the emergency room. Another bolus dose of tirofiban was administered at least 10 minutes before the first balloon inflation, followed by a maintenance infusion of 0.15 µg per minute for 18 to 24 hours. Heparin was given as an initial bolus of 70 U per kilogram (maximum, 7500 U). If necessary, an additional bolus was administered to achieve an activated clotting time ≥ 250 seconds. Early femoral sheath removal was performed when an activated clotting time was less than 180 seconds. Ticlopidine was given for at least 2 weeks to patients who underwent primary stenting and aspirin (100 mg orally once a day) was administered to each patient indefinitely. Angiographic analysis: Quantitative angiographic analyses of the percentage of stenosis, lesion length, minimal lumen diameter (MLD), and reference lumen diameter (RLD) were performed using a digital edge-detection algorithm 18) and selecting end-diastolic frames demonstrating the stenosis in its most severe and nonforeshortened projection. With the contrast-filled guiding catheter used as the calibration standard, the RLD and MLD were calculated before and after stenting. Definitions: AMI was defined as typical chest pain lasting for more than 30 minutes with ST-se > 1 mm in two consecutive precordial or inferior leads. Reperfusion time was defined as the time from symptom onset of chest pain to first balloon inflation. Procedural success was defined as successful stent deployment at the desired position with a residual stenosis of < 20% followed by TIMI grade 3 flow in the IRA. Multivessel disease was defined by stenoses of > 50% in ≥ 2 major epicardial coronary arteries. Unsuccessful reperfusion was defined as a final TIMI flow ≤ 2 in the IRA after primary stenting. Recurrent ischemia was defined as recurrent chest pain > 20 minutes with a new ischemic electrocardio-graphic change. If these findings were associated with at least a 50% increase in a previous CK-MB trough, reinfarction was diagnosed. Angiographic restenosis was defined as ≥ 50% stenosis of a previous targeted lesion of the IRA. Data collection: In our hospital, all patients with AMI underwent primary PCI after informed consent was obtained. For the purpose of the study, all patients undergoing primary PCI were prospectively identified. Detailed in-hospital and follow-up data including age, sex, coronary risk factors, Killip score on admission, reperfusion time, pre-and postintervention TIMI flow grades, number of diseased vessels, and in-hospital adverse events were obtained. These data were collected prospectively and entered into a computerized database. Statistical analysis: Data were expressed as the mean ± SD. Continuous variables were compared using the Wilcoxon rank-sum test. Categorical variables were compared using chi-square or Fischer's exact test. Stepwise logistic regression analysis was used to determine independent predictors of combined slow flow and no reflow after primary stenting. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC). A probability value < 0.05 was considered statistically significant.
RESULTS
Comparison of baseline characteristics, clinical features, angiographic results, and combined major cardiac events between the two groups (Tables I and II):
Relevant patient baseline characteristics, angiographic results, and 30-day and 6- Tables I and II . There were no significant differences in terms of age, sex, coronary risk factors, previous MI, old stroke, infarction locations, incidences of cardiogenic or noncardiogenic shock, and reperfusion time between the study and control group patients. The mean duration between administration of the first loading dose of tirofiban and first balloon inflation was 24 ± 14.3 minutes. Data are expressed as mean value ± SD or number (%) of patients. TIMI = thrombolysis in myocardial infarction; MLD = minimal lumen diameter; RLD = reference lumen diameter; PCI = percutaneous coronary intervention; IRA = infarctrelated artery.
Angiographic findings demonstrated that there were no significant differences in the IRA, incidence of multivessel disease, preinterventional TIMI flow grades, pre-and postinterventional MLD, RLD and percentage of stenosis, or lesion length between the study and control group patients. Moreover, there no significant differences in an RLD ≥ 3.5 mm of IRA between the control and study groups. Furthermore, angiographic results demonstrated that there were no significant differences in successful or unsuccessful reperfusion rates between the study and control group patients.
The overall 30-day mortality rate was 6.0%. There were no significant differences in 30-day mortality (5.3% vs 6.6%, P = 0.639) or combined major cardiac events between the study and control group patients. However, the 30-day mortality rate was significantly higher in patients with unsuccessful reperfusion than in patients with successful reperfusion [20.0% (8/40) vs 3.5% (8/229), P < 0.0001].
The angiographic follow-up rate was 76.2% in the study group and 84.3% in the control group. There were no significant differences in restenosis of IRA, repeated PCI of IRA, or 6-month mortality rate. (Tables III and   IV) : Univariate analysis of the factors associated with unsuccessful reperfusion after primary stenting in the study group is shown in Table III . The most signifi- cant factor among these variables was an RLD of IRA ≥ 3.5 mm. A lesion length of ≥ 20.0 mm and nonanterior wall infarction were significantly related to increased unsuccessful reperfusion. Cardiogenic shock had a statistically significant, but weak tendency (P = 0.048) related to unsuccessful reperfusion.
Determinants of unsuccessful reperfusion in study group patients
The incidence of RLD of the IRA ≥ 3.5 mm was significantly higher in patients with nonanterior wall than in those patients with anterior wall infarction [52.2% (24/46) vs 26.4% (23/87), P = 0.0031]. However, there was no significant difference in unsuccessful reperfusion with respect to an RLD of the IRA ≥ 3.5 mm between nonanterior wall and anterior wall infarction [33.3% (8/24) vs 26.1% (6/23), P = 0.9].
By multiple stepwise logistic regression analysis (Table IV) , only an RLD of the IRA ≥ 3.5 mm and a lesion length of ≥ 20.0 mm were significant independent predictors of an increase in unsuccessful reperfusion.
DISCUSSION
Ruptured or fissuring plaque precipitating thrombus formation, which in turn, leads to acute occlusion of the coronary artery is a universally understood mechanism for AMI. Therefore, it has been suggested that incremental antiplatelet therapy by GP IIb/IIIa receptor blockers might attenuate the formation of a new platelet-rich thrombus and thereby improve the outcome of primary PCI. 7, 15, 16) Recently, the PRISM-PLUS clinical trial 17) reported that the addition of tirofiban to heparin reduced the thrombus burden of the culprit lesion and improved distal perfusion in patients with unstable angina or non-Q-wave myocardial infarction. However, our present study demonstrated that compared with primary stenting alone, a combination therapy of early administration of tirofiban and primary stenting for treatment of ST-se AMI did not provide additional benefits for normal coronary blood flow in the IRA, in reducing major cardiac events within 30 days of infarction, or in the 6 month angiographic results or clinical outcomes.
Inconclusive results in recent clinical trials: Recently, abciximab, which is another platelet glycoprotein IIb/IIIa receptor inhibitor, has also been investigated extensively in several clinical trials. 7, 15, 16, 19, 20) The short-term clinical outcomes of primary PCI have been improved by adjunctive pharmacologic therapy with abciximab. 7, 15, 16) However, if complete reperfusion of the IRA is considered a successful therapeutic end point, the results were not different between balloon angioplasty alone and balloon angioplasty plus abciximab in the RAPPORT Trial 7) or between stenting alone and stenting plus abciximab in the CADILLAC Trial. 19) Furthermore, when we carefully analyze the data from the RAPPORT trial, 7) only urgent target vessel revascularization and combined major cardiac events were statistically significant clinical benefits. The results from these two trials 7, 19) suggest that the benefits of adjunctive abciximab therapy shown in the RAPPORT trial, 7) including reducing urgent target vessel revascularization and reducing combined major cardiac events, were abolished by primary stenting in the CADILLAC trial. 19) In contrast to the CADILLAC trial, 19) the ADMIRAL trial 16) demonstrated that abciximab can provide additional clinical benefits when administered in conjunction with primary stenting for the treatment of AMI. Moreover, Van de Werf, et al 21) have recently recommended that trial data on adjunctive antiplatelet therapy for AMI are still inconclusive. Therefore, the discrepancy in these studies suggests that there are other unidentified confounders. Impact of thrombus burden on myocardial reperfusion: In the present study, we found that an RLD of the IRA ≥ 3.5 mm and a lesion length ≥ 3.5 mm were the independent predictors of unsuccessful reperfusion. Our finding was consistent with recent studies 22, 23) which demonstrated that large vessels usually contain large amounts of plaque burden and high-burden thrombus formation. Furthermore, our clinical observations led us understand that the longer the lesion length, the greater the plaque burden. During coronary intervention, the thrombus is crushed and the plaque is artificially ruptured, which in turn, cause a release of macro-and microthrombus, and lipid pool-like contents. 22, 23) These materials subsequently cause macro-and microembolism, and microvascular dysfunction. 22, 23) The dislodged thrombi further activate more platelets and therefore, the thrombosis cascade, and this ultimately yields slow-flow or no-reflow in the IRA. Therefore, the large IRA and the longer lesion length had a mutual interaction which appeared to be a determinant for unsuccessful reperfusion. Moreover, we suggest that large vessels frequently contained high-burden thrombi which cannot be lysed by GP IIb/IIIa. This hypothesis, derived from clinical observation, was supported by the TIMI 14 substudy 24) and PRISM-PLUS clinical trial. 17) These two studies demonstrated that adjunctive therapy with abciximab 24) in patients with AMI resulted in only partial lysis of the thrombus, and adjunctive tirofiban therapy 17) in patients with unstable angina or non-Q-wave myocardial infarction usually resulted in residual thrombus in the large right coronary artery. Recently, using quantitative and immunohistochemical analysis of intracoronary thrombus aspirated by a Rescue TM PT catheter in patients with AMI, Fujii and associates showed that more than 70% of the surface area of high burden intracoronary thrombus consists of red blood cells and more than 70% of the surface area of low burden intracoronary thrombus consists of platelets. 25) This may further explain the ineffectiveness of PG IIb/IIIa inhibitors in reducing the no reflow phenomenon in patients with high burden intracoronary thrombus.
Our study has several limitations. First, due to ethical reasons, we used a prospective, nonrandomized study. However, this study proceeded in a chronologically consecutive manner which is an approach that eliminates the potential for operator bias in selecting one specific strategic management over the other. Second, the optimal dosage and timing of tirofiban administration to achieve inhibition of most (85%) platelet activity in the clinical setting of AMI are unknown. Although a double loading dose of tirofiban was used in this study and the mean duration between administration of the first loading dose of tirofiban and first balloon inflation was 24 ± 14.3 minutes, the incidences of successful reperfusion and short-term cardiac events were not different between patients with and without adjunctive tirofiban therapy. Third, adjunctive tirofiban therapy may provide an additional benefit beyond the epicardial arterial flow, and myocardial contrast echo, ST-segment resolution, and angiographic "blushing" scores may provide a more meaningful assessment of reperfusion efficacy than TIMI flow grade in this situation. However, our study did not assess reperfusion other than the TIMI flow grade. Moreover, TIMI flow grade is still the most common assessment for reperfusion. Finally, the effectiveness of adjunctive mechanical removal of intracoronary thrombi with an angioject rheolytic thrombectomy catheter, 26) PercuSurge GuardWire distal balloon protection device, 27) or AngioGuard emboli capture guidewire system 28) to overcome the no reflow phenomenon was not assessed in this study.
In conclusion, the present study has demonstrated that adjunctive tirofiban therapy in ST-se AMI did not provide additional benefits in the angiographic and short-term clinical outcomes compared to conventional primary stenting. An RLD of the IRA ≥ 3.5 mm and a lesion length ≥ 20.0 mm were strongly associated with unsuccessful reperfusion.
